

In another aspect, there is provided use of a compound of formula I as defined herein in the manufacture of a medicament for the treatment or prevention of a disease in which DPPI activity inhibitors have a therapeutic benefit, wherein said disease is selected from the group consisting of asthma and allergic disease, gastrointestinal inflammatory disease, glomerulonephritis, eosinophilic disease, chronic obstructive pulmonary disease, infection
5 by pathogenic microbes, rheumatoid arthritis, neutrophilic diseases, cystic fibrosis (CF), non-cystic fibrosis, idiopathic pulmonary fibrosis, bronchiectasis, ANCA-associated vasculitis, lung cancer, emphysema, chronic bronchitis, acute lung injury (ALI), acute respiratory distress syndrome (ARDS), pulmonary hypertension, pulmonary arterial
10 hypertension (PAH) and Alpha-1-antitrypsin deficiency (AATD), obesity and related inflammation, insulin resistance, diabetes, fatty liver and liver steatosis.


In another aspect, there is provided a pharmaceutical composition comprising additionally to a compound of formula I as defined herein, a pharmaceutically active compound
15 selected from the group consisting of betamimetics, anticholinergics, corticosteroids, PDE4-inhibitors, LTD4-antagonists, EGFR-inhibitors, CRTH2 inhibitors, 5-LO-inhibitors, Histamine receptor antagonists, CCR9 antagonists and SYK-inhibitors, NE-inhibitors, MMP9 inhibitors, MMP12 inhibitors, but also combinations of two or three active substances.

20

PREFERRED EMBODIMENTS

Particularly preferred are the above compounds of formula I, or a pharmaceutically acceptable salt thereof, wherein


Cy is



25

Preferred are the above compounds of formula I, or a pharmaceutically acceptable salt thereof, wherein

Cy is



Preferred are the above compounds of formula I, or a pharmaceutically acceptable salt
5 thereof, wherein
R¹ is selected from the group consisting of H, CH₃- and oxetanyl.

27. Pharmaceutical composition, characterised in that it contains one or more compounds of formula I according to any one of claims 1 to 24 or a pharmaceutically active salt thereof.

28. Use of a compound of formula I according to one of claims 1 to 24 in the manufacture of a medicament for the treatment or prevention of a disease in which DPPI activity inhibitors have a therapeutic benefit, wherein said disease is selected from the group consisting of asthma and allergic disease, gastrointestinal inflammatory disease, glomerulonephritis, eosinophilic disease, chronic obstructive pulmonary disease, infection by pathogenic microbes, rheumatoid arthritis, neutrophilic diseases, cystic fibrosis (CF), non-cystic fibrosis, idiopathic pulmonary fibrosis, bronchiectasis, ANCA-associated vasculitis, lung cancer, emphysema, chronic bronchitis, acute lung injury (ALI), acute respiratory distress syndrome (ARDS), pulmonary hypertension, pulmonary arterial hypertension (PAH) and Alpha-1-antitrypsin deficiency (AATD), obesity and related inflammation, insulin resistance, diabetes, fatty liver and liver steatosis.

29. A pharmaceutical composition comprising additionally to a compound of formula I, according to any one of claims 1 to 24, a pharmaceutically active compound selected from the group consisting of betamimetics, anticholinergics, corticosteroids, PDE4-inhibitors, LTD4-antagonists, EGFR-inhibitors, CRTH2 inhibitors, 5-LO-inhibitors, Histamine receptor antagonists, CCR9 antagonists and SYK-inhibitors, NE-inhibitors, MMP9 inhibitors, MMP12 inhibitors, but also combinations of two or three active substances.